Annual Meeting Webinar #2: Paradigm Changes in Front Line Ovarian Cancer
All times listed are Central Daylight Time (CDT).
Moderators/Distillants: Thomas J. Herzog, MD, and Kathleen N. Moore, MD
- Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by BRCA and homologous recombination status: PRIMA/ENGOT-OV26/GOG-3012 study – B. J. Monk
- Time to first subsequent therapy (TFST) and progression-free survival 2 (PFS2) from the phase 3 randomized, double-blind PRIMA/ENGOT-OV26/GOG-3012 study in patients with newly diagnosed ovarian cancer – S. N. Han
- Phase III PAOLA-1/ENGOT-ov25: maintenance olaparib with bevacizumab in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy and bevacizumab as standard of care – I. Ray-Coquard
- Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial – C. Grimm
- Population adjusted indirect comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 studies of olaparib with or without bevacizumab, bev alone and placebo in the maintenance treatment of women with newly diagnosed stage III/IV ovarian cancer with BRCA mutation – I. B. Vergote
- Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC) – R. Coleman
- Anti-tumor activity of veliparib during combination phase with chemotherapy in VELIA study – D. O’Malley
- Describe the continuum of benefit to niraparib across homologous recombination subgroups in the PRIMA/OV-26/GOG-3012 trial of patients with newly diagnosed ovarian cancer.
- Describe outcomes of secondary endpoints from the PRIMA/OV-26/GOG-3012
- Demonstrate the efficacy and tolerability of maintenance therapy with olaparib plus bevacizumab versus bevacizumab alone in patients with advanced high-grade ovarian cancer in response to first-line platinum-based chemotherapy plus bevacizumab.
- Demonstrate the efficacy of maintenance therapy with olaparib plus bevacizumab according to surgical timing and residual disease in women with advanced high-grade ovarian cancer in response to first-line platinum-based chemotherapy plus bevacizumab.
- Present the results of a population-adjusted indirect treatment comparison that used data from the Phase III SOLO1 and PAOLA-1 trials to assess the comparative efficacies of maintenance therapies from these trials in patients with newly diagnosed advanced BRCA-mutated ovarian cancer.
- Demonstrate the role of veliaparib in the treatment of primary advanced ovarian cancer
- Delineate clearly the objective response rates observed in patients treated with veliparib in combination with chemotherapy
In support of improving patient care, the Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
AMA Credit Designation Statement – Physicians
The Society of Gynecology Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation on each activity.
ANCC Credit Designation Statement – Nurses
This activity has been approved for a maximum of 1.0 nursing contact hours.
ACPE Credit Designation Statement – Pharmacists
Each activity has been approved for a maximum of 1.0 contact hours of pharmacy continuing education credit. UAN number JA00007238-0000-20-006-L01-P.
PAs may claim a maximum of 1.0 AMA PRA Category 1 Credits™ for completing this live activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state or medical society.a